A Massachusetts-based biotechnology company pioneering messenger RNA (mRNA) vaccines announced that the first participant was recently dosed in the Phase 1/2 study of Moderna’s vaccine candidate against COVID-19 in Japan.
Moderna, Inc confirmed this clinical trial is led by Takeda Pharmaceutical Co., based in Osaka, Japan.
TAK-919 is Takeda’s development code for Moderna’s COVID-19 vaccine candidate, known as mRNA-1273.
Read More
